Cardiac Transplantation and the Use of Cannabis.
Hirak ShahMeg FraserArianne Clare C AgdamagValmiki MaharajBellony NzemenohCindy M MartinTamas AlexyDaniel J GarryPublished in: Life (Basel, Switzerland) (2021)
Cardiac transplantation requires the careful allocation of a limited number of precious organs. Therefore, it is critical to select candidates that will receive the greatest anticipated medical benefit but will also serve as the best stewards of the organ. Individual transplant teams have established prerequisites pertaining to recreational drug, tobacco, alcohol, and controlled substance use in potential organ recipients and post-transplantation. Legalization of cannabis and implementation of its prescription-based use for the management of patients with chronic conditions have been increasing over the past years. Center requirements regarding abstinence from recreational and medical cannabis use vary due to rapidly changing state regulations, as well as the lack of clinical safety data in this population. This is evident by the results of the multicenter survey presented in this paper. Developing uniform guidelines around cannabis use will be imperative not only for providers but also for patients.
Keyphrases
- healthcare
- end stage renal disease
- left ventricular
- ejection fraction
- newly diagnosed
- cross sectional
- cell therapy
- primary care
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- clinical practice
- patient reported outcomes
- clinical trial
- electronic health record
- big data
- machine learning
- smoking cessation
- bone marrow
- drug induced
- patient reported
- kidney transplantation